Showing results (231-240 of 632) with videos related to

Sort By:
Pageof 64
The American Journal of Psychiatry|May 2, 2006
A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndromeJohn P O'Reardon, Kelly C Allison, Nicole S Martino, et al.
Scandinavian Journal of Infectious Diseases|January 1, 1995
Pneumocystis carinii in bronchoalveolar lavage and induced sputum: detection with a nested polymerase chain reactionJ Skøt, A G Lerche, H J Kolmos, et al.
The Journal of Infectious Diseases|May 1, 1994
Differential effect on serum neopterin and serum beta 2-microglobulin is induced by treatment in Pneumocystis carinii pneumoniaT L Benfield, J K Schattenkerk, B Hofmann, et al.
Journal of Human Genetics|December 25, 2019
Variant in ERAP1 promoter region is associated with low expression in a patient with a Behçet-like MHC-I-opathyChrysoula Dimopoulou, Jens D Lundgren, Jon Sundal, et al.
Psychiatry Research|February 19, 2008
123I-ADAM SPECT imaging of serotonin transporter binding in patients with night eating syndrome: a preliminary reportJennifer D Lundgren, Andrew B Newberg, Kelly C Allison, et al.
Journal of Biological Rhythms|October 18, 2013
Daily physical activity patterns of children with delayed eating behaviorsAnnette R Gallant, Marie-Eve Mathieu, Jennifer D Lundgren, et al.
AIDS (London, England)|March 1, 1990
Opportunistic infections and malignancies in 231 Danish AIDS patientsC Pedersen, J Gerstoft, P Tauris, et al.
AIDS (London, England)|September 23, 2003
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosineJan Gerstoft, Ole Kirk, Niels Obel, et al.
HIV Medicine|December 12, 2001
Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohortO Kirk, J Gerstoft, C Pedersen, et al.
Transplantation Proceedings|December 23, 2018
Hyaluronic Acid Is a Biomarker for Allograft Dysfunction and Predicts 1-Year Graft Loss After Liver TransplantationA A Rostved, S R Ostrowski, L Peters, et al.
Pageof 64